Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc

In a report released today, Richard Hightower from Barclays assigned a Buy rating to Prologis, with a price target of $156.00. Hightower covers the...

Prologis (PLD) Gets a Buy from Barclays

Berenberg Bank analyst Will Dalby reiterated a Buy rating on Kodal Minerals on July 17 and set a price target of p1.00. The company’s shares closed...

Berenberg Bank Remains a Buy on Kodal Minerals (KOD)

Wells Fargo analyst Blaine Heck maintained a Buy rating on Prologis yesterday and set a price target of $180.00. The company’s shares closed yester...

Prologis (PLD) Receives a Buy from Wells Fargo

Barclays analyst Brendan Lynch maintained a Buy rating on Prologis today and set a price target of $156.00. According to TipRanks, Lynch is an anal...

Prologis ( ($PLD) ) just unveiled an announcement. On June 29, 2026, Prologis appointed former Visa chief executive Alfred F. Kelly, Jr. to its boa...

Prologis Adds Former Visa CEO to Board

Prologis ( ($PLD) ) just unveiled an announcement. On June 29, 2026, Prologis’ board of directors appointed Alfred F. Kelly, Jr. as an independent ...

Prologis Adds Alfred Kelly to Board of Directors

Wells Fargo analyst Blaine Heck assigned a Buy rating to Prologis today and set a price target of $167.00. Heck covers the Real Estate sector, focu...

Wells Fargo Releases a Buy Rating on Prologis (PLD)

Prologis ( ($PLD) ) has shared an update. Prologis has published an investor presentation outlining the strategic and financial case for a possible...

Prologis Sets Out Case for Possible All-Share Combination With SEGRO

An update from Kodal Minerals ( ($GB:KOD) ) is now available. Kodal Minerals reported that all resolutions at its Annual General Meeting were appro...

Kodal Minerals AGM Passes All Resolutions as Director Steps Down

Kodal Minerals ( ($GB:KOD) ) has shared an announcement. Kodal Minerals reported a transformational nine‑month period to 31 December 2025 as it mov...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KOD	$40.87	-4.15%	500.82K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KOD	$40.87	-4.2%	500.82K
3
4
5
6

KOD

KOD

Get Kodiak Sciences Inc Data in Excel

Get Kodiak Sciences Inc Data in Excel